Short Interest in Grifols, S.A. (NASDAQ:GRFS) Drops By 28.9%

Grifols, S.A. (NASDAQ:GRFS) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 2,710,000 shares, a decline of 28.9% from the February 28th total of 3,810,000 shares. Based on an average daily volume of 991,800 shares, the short-interest ratio is currently 2.7 days. Currently, 1.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Grifols

Institutional investors have recently made changes to their positions in the company. Capital World Investors boosted its holdings in Grifols by 0.7% during the fourth quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company’s stock worth $157,239,000 after buying an additional 154,358 shares in the last quarter. Brandes Investment Partners LP raised its position in shares of Grifols by 3.0% in the fourth quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company’s stock worth $152,491,000 after acquiring an additional 592,096 shares during the period. Black Creek Investment Management Inc. boosted its stake in shares of Grifols by 1.3% during the 4th quarter. Black Creek Investment Management Inc. now owns 11,251,960 shares of the biotechnology company’s stock worth $83,715,000 after acquiring an additional 141,615 shares in the last quarter. Soleus Capital Management L.P. grew its position in shares of Grifols by 46.1% during the 4th quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company’s stock valued at $49,144,000 after acquiring an additional 2,083,722 shares during the period. Finally, Whitebox Advisors LLC grew its position in shares of Grifols by 56.2% during the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock valued at $37,487,000 after acquiring an additional 1,519,093 shares during the period.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley started coverage on Grifols in a research report on Wednesday, February 12th. They set an “overweight” rating on the stock.

Grifols Stock Performance

GRFS stock traded down $0.16 during trading on Monday, hitting $7.11. 1,156,487 shares of the company traded hands, compared to its average volume of 1,231,193. Grifols has a 1 year low of $5.79 and a 1 year high of $9.96. The company has a market cap of $4.89 billion, a PE ratio of 6.08 and a beta of 0.35. The stock’s 50-day simple moving average is $7.56 and its 200 day simple moving average is $8.04. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.